ClinicalTrials.gg
CompletedNCT00664326Updated Jan 29, 2021Results posted

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

A Phase 2 interventional study of Regorafenib (Stivarga, BAY73-4506) in Carcinoma, Renal Cell, sponsored by Bayer. Completed at 18 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Carcinoma, Renal Cell by Bayer — none open to participants now, 1 under way, none of them phase 3. Carcinoma, Renal Cell · Bayer.

Enrollment
11th of 17
49 · median 83
Started
2008
with 6 others
Phase 2
10 of 29
none open now
Registered
14th of 29
by date

Among the 29 studies in Carcinoma, Renal Cell by Bayer, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2008, is one of 10 in phase 2, and was the 14th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

None of the 29 studies in Carcinoma, Renal Cell by Bayer is open now. The open studies under Carcinoma, Renal Cell, anywhere →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Carcinoma, Renal Cell by Bayer as a file.
02

Study summary

This is a uncontrolled, open-label, non-randomized Phase II study of oral BAY73-4506 to evaluate the response rate of BAY73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).

Read the detailed description

The final analysis of efficacy will be performed after last patient has been treated for at least 6 months. Additional periodic safety and efficacy data reviews will be performed for any patients continuing to receive study drug afterwards.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients >/= 18 years of age.
  • Patients, who suffer from unresectable and/or , measurable predominantly clear cell RCC (renal cell carcinoma histologically) or documented.
  • Patients must be previously untreated for advanced disease. Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.
  • Patients who have at least one uni-dimensional by computed tomography (CT-scan) or magnetic resonance imaging (MRI) according to (RECIST).
  • Patients with "Intermediate" or "Low" risk per the Motzer score.
  • Patients who have an Eastern Co-operative Oncology Group () performance status of 0 or 1.
  • Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment

Exclusion criteria

Exclusion Criteria:

  • Patients who have received prior systemic treatment regimens for RCC.
  • Uncontrolled/unstable cardiac disease
  • Uncontrolled hypertension
  • Active clinically serious infections (> [CTCAE] grade 2 )
  • History of (HIV) infection or chronic or C.
  • Known history or symptomatic brain or meningeal tumours
  • Patients with seizure disorder requiring medication
  • Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >/= CTCAE Grade 3 within 4 weeks of first dose of study.
  • Pregnant or breast-feeding patients
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Regorafenib (Stivarga, BAY73-4506)

    Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle

    Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

  • Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response

    Objective tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\] or Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\]) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) committee.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

  2. Tumor Response

    Tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\], Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\], Stable Disease \[SD, steady state of disease\], or Progressive Disease \[PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\]) observed during trial period assessed according to the RECIST committee.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

Secondary outcomes

  1. Disease Control

    Disease control was defined as the percentage of participants who had a best response rating of CR (tumor disappears), PR (sum of lesion sizes decreased at least 30% from baseline), or SD (steady state of disease) that was maintained for at least 28 days from the first demonstration of that rating.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

  2. Overall Survival

    Overall survival (OS) was calculated as the time from the first date of receiving study medication to death, due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009).

  3. Progression-free Survival (PFS)

    PFS was calculated as time from first date of receiving study drug until date of first observed disease progression (PD) (radiological or clinical, whichever was earlier) or death due to any cause, if death occurred before PD was documented. The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD or death at time of analysis were censored at last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

  4. Time to Progression (TTP)

    TTP was calculated as time from first date of receiving study drug until date of first documented disease progression (PD) (radiological or clinical, whichever was earlier). The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than the scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD at time of analysis were censored at last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

  5. Duration of Response

    Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was earlier, to disease progression or death (if death occurred before progression was documented). Duration of response for subjects who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

  6. Duration of Stable Disease (SD)

    Duration of SD was calculated as the time from the first date of receiving study drug until the date of documented PD or the last observation if the subject did not progress. Subjects without disease progression at the time of analysis were censored at the last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks

Other outcomes

  1. Objective Tumor Response (Update)

    Objective tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\] or Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\]) observed during trial period assessed according to the RECIST committee.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  2. Tumor Response (Update)

    Tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\], Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\], Stable Disease \[SD, steady state of disease\], or Progressive Disease \[PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\]) observed during trial period assessed according to the RECIST committee.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  3. Disease Control (Update)

    Disease control was defined as the percentage of participants who had a best response rating of CR (tumor disappears), PR (sum of lesion sizes decreased at least 30% from baseline), or SD (steady state of disease) that was maintained for at least 28 days from the first demonstration of that rating.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  4. Overall Survival (Update)

    Overall survival (OS) was calculated as the time from the first date of receiving study medication to death, due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011).

  5. Progression-free Survival (Update)

    PFS was calculated as time from first date of receiving study drug until date of first observed disease progression (PD) (radiological or clinical, whichever was earlier) or death due to any cause, if death occurred before PD was documented. The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD or death at time of analysis were censored at last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  6. Time to Progression (Update)

    TTP was calculated as time from first date of receiving study drug until date of first documented disease progression (PD) (radiological or clinical, whichever was earlier). The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than the scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD at time of analysis were censored at last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  7. Duration of Response (Update)

    Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was earlier, to disease progression or death (if death occurred before progression was documented). Duration of response for subjects who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

  8. Duration of Stable Disease (Update)

    Duration of SD was calculated as the time from the first date of receiving study drug until the date of documented PD or the last observation if the subject did not progress. Subjects without disease progression at the time of analysis were censored at the last date of tumor evaluation.

    Time frame: From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks

07

Results

Posted Nov 28, 2012

Participant flow

Male or female untreated participants, who were at least 18 years of age, with metastatic and/or unresectable, measurable predominantly clear cell renal cell cancer (RCC) histologically or cytologically documented could participate in this study at 18 centers in 6 countries.

Participant flow — Overall Study
MilestoneRegorafenib (Stivarga, BAY73-4506)
Started49
Completed1
Not completed48
Withdrew: Adverse event14
Withdrew: Noncompliance with study medication3
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1
Withdrew: Other reasons3
Withdrew: Death2
Withdrew: Disease progression/recurrence/relapse24

Outcome measures

PrimaryObjective Tumor Response

Objective tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\] or Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\]) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) committee.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Objective Tumor Response
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Objective Tumor Response31.3
PrimaryTumor Response

Tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\], Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\], Stable Disease \[SD, steady state of disease\], or Progressive Disease \[PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\]) observed during trial period assessed according to the RECIST committee.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Tumor Response
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Complete Response (CR)0.0
Partial Response (PR)31.3
Stable Disease (SD)50.0
Progressive Disease (PD)10.4
Not Assessable8.3
SecondaryDisease Control

Disease control was defined as the percentage of participants who had a best response rating of CR (tumor disappears), PR (sum of lesion sizes decreased at least 30% from baseline), or SD (steady state of disease) that was maintained for at least 28 days from the first demonstration of that rating.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Disease Control
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Disease Control62.5
SecondaryOverall Survival

Overall survival (OS) was calculated as the time from the first date of receiving study medication to death, due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009).
Reported as:
Median · Days
Overall Survival
DaysRegorafenib (Stivarga, BAY73-4506)
Overall SurvivalNA (285 to NA)
SecondaryProgression-free Survival (PFS)

PFS was calculated as time from first date of receiving study drug until date of first observed disease progression (PD) (radiological or clinical, whichever was earlier) or death due to any cause, if death occurred before PD was documented. The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD or death at time of analysis were censored at last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysRegorafenib (Stivarga, BAY73-4506)
Progression-free Survival (PFS)251 (160 to NA)
SecondaryTime to Progression (TTP)

TTP was calculated as time from first date of receiving study drug until date of first documented disease progression (PD) (radiological or clinical, whichever was earlier). The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than the scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD at time of analysis were censored at last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Time to Progression (TTP)
DaysRegorafenib (Stivarga, BAY73-4506)
Time to Progression (TTP)251 (167 to NA)
SecondaryDuration of Response

Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was earlier, to disease progression or death (if death occurred before progression was documented). Duration of response for subjects who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Duration of Response
DaysRegorafenib (Stivarga, BAY73-4506)
Duration of ResponseNA (140 to NA)
SecondaryDuration of Stable Disease (SD)

Duration of SD was calculated as the time from the first date of receiving study drug until the date of documented PD or the last observation if the subject did not progress. Subjects without disease progression at the time of analysis were censored at the last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 13 months later (13May2008 - 31May2009). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Duration of Stable Disease (SD)
DaysRegorafenib (Stivarga, BAY73-4506)
Duration of Stable Disease (SD)172 (107 to NA)
Other pre-specifiedObjective Tumor Response (Update)

Objective tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\] or Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\]) observed during trial period assessed according to the RECIST committee.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Objective Tumor Response (Update)
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Objective Tumor Response (Update)39.6
Other pre-specifiedTumor Response (Update)

Tumor response of a participant was defined as the best tumor response (confirmed Complete Response \[CR, tumor disappears\], Partial Response \[PR, sum of lesion sizes decreased at least 30% from baseline\], Stable Disease \[SD, steady state of disease\], or Progressive Disease \[PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\]) observed during trial period assessed according to the RECIST committee.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Tumor Response (Update)
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Complete Response (CR)0.0
Partial Response (PR)39.6
Stable Disease (SD)41.7
Progressive Disease (PD)10.4
Not Assessable8.3
Other pre-specifiedDisease Control (Update)

Disease control was defined as the percentage of participants who had a best response rating of CR (tumor disappears), PR (sum of lesion sizes decreased at least 30% from baseline), or SD (steady state of disease) that was maintained for at least 28 days from the first demonstration of that rating.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Number · Percentage of participants
Disease Control (Update)
Percentage of participantsRegorafenib (Stivarga, BAY73-4506)
Disease Control (Update)62.5
Other pre-specifiedOverall Survival (Update)

Overall survival (OS) was calculated as the time from the first date of receiving study medication to death, due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011).
Reported as:
Median · Days
Overall Survival (Update)
DaysRegorafenib (Stivarga, BAY73-4506)
Overall Survival (Update)NA (735 to NA)
Other pre-specifiedProgression-free Survival (Update)

PFS was calculated as time from first date of receiving study drug until date of first observed disease progression (PD) (radiological or clinical, whichever was earlier) or death due to any cause, if death occurred before PD was documented. The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD or death at time of analysis were censored at last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Progression-free Survival (Update)
DaysRegorafenib (Stivarga, BAY73-4506)
Progression-free Survival (Update)335 (167 to 438)
Other pre-specifiedTime to Progression (Update)

TTP was calculated as time from first date of receiving study drug until date of first documented disease progression (PD) (radiological or clinical, whichever was earlier). The actual date of tumor assessments (i.e., date on which radiological procedure was performed, rather than the scheduled date) was used for this calculation to determine both the event date and censoring date. Patients without PD at time of analysis were censored at last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Time to Progression (Update)
DaysRegorafenib (Stivarga, BAY73-4506)
Time to Progression (Update)335 (167 to 454)
Other pre-specifiedDuration of Response (Update)

Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was earlier, to disease progression or death (if death occurred before progression was documented). Duration of response for subjects who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Duration of Response (Update)
DaysRegorafenib (Stivarga, BAY73-4506)
Duration of Response (Update)428 (250 to 540)
Other pre-specifiedDuration of Stable Disease (Update)

Duration of SD was calculated as the time from the first date of receiving study drug until the date of documented PD or the last observation if the subject did not progress. Subjects without disease progression at the time of analysis were censored at the last date of tumor evaluation.

Time frame:
From start of treatment of the first participant until database cut-off approximately 37 months later (13May2008 - 1Jun2011). Assessed every 8 weeks for 6 months, then every 12 weeks
Reported as:
Median · Days
Duration of Stable Disease (Update)
DaysRegorafenib (Stivarga, BAY73-4506)
Duration of Stable Disease (Update)119 (105 to 335)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib (BAY73-4506)39/49 (79.6%)32/49 (65.3%)48/49 (98%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventRegorafenib (BAY73-4506)
Renal failureRenal and urinary disorders4/49
Cardiac arrestCardiac disorders2/49
Myocardial infarctionCardiac disorders2/49
Chest painGeneral disorders2/49
General physical health deteriorationGeneral disorders2/49
SyncopeNervous system disorders2/49
Pleural effusionRespiratory, thoracic and mediastinal disorders2/49
Angina unstableCardiac disorders1/49
Atrial fibrillationCardiac disorders1/49
Abdominal painGastrointestinal disorders1/49
Most frequent other events
Showing 10 of 62
Most frequent other events
EventRegorafenib (BAY73-4506)
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders34/49
HypertensionVascular disorders25/49
DiarrhoeaGastrointestinal disorders24/49
FatigueGeneral disorders22/49
AlopeciaSkin and subcutaneous tissue disorders22/49
DysphoniaRespiratory, thoracic and mediastinal disorders18/49
ConstipationGastrointestinal disorders17/49
RashSkin and subcutaneous tissue disorders17/49
NauseaGastrointestinal disorders16/49
Decreased appetiteMetabolism and nutrition disorders16/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Regorafenib (Stivarga, BAY73-4506)
Median62.0 (40 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib (Stivarga, BAY73-4506)
Female22
Male27
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants)Regorafenib (Stivarga, BAY73-4506)
030
119
Overall Motzer Score
Overall Motzer Score(Participants)Regorafenib (Stivarga, BAY73-4506)
Low24
Intermediate25
08

Study locations

18 sites
  • Los Angeles, California 90033, United States
  • Houston, Texas 77030, United States
  • Helsinki, 00290, Finland
  • Turku, FIN-20521, Finland
  • Nantes, 44020, France
  • Paris, 75014, France
  • Frankfurt, Hessen 60596, Germany
  • Dresden, Sachsen 01307, Germany
  • Berlin, 10967, Germany
  • Hamburg, 20246, Germany
  • Bialystok, 15-027, Poland
  • Lublin, 20-090, Poland
  • Poznan, 60-569, Poland
  • Leicester, Leicestershire LE1 5WW, United Kingdom
  • Bristol, BS2 8ED, United Kingdom
  • Cambridge, CB2 0QQ, United Kingdom
  • London, SE1 9RT, United Kingdom
  • Northwood, HA6 2RN, United Kingdom
09

References and documents

Publications

  • Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012 Oct;13(10):1055-62. doi: 10.1016/S1470-2045(12)70364-9. Epub 2012 Sep 6. PubMed 22959186 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2008 to primary completion in May 2009, 13 months.

Results were first posted in Nov 2012, 3 years 5 months after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 13 months is below that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2008
First posted
Apr 22, 2008
StartActual
Apr 30, 2008
Primary completionActual
May 31, 2009
CompletionActual
Apr 2, 2019
Results first posted
Nov 28, 2012
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00664326
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 22, 2008
Start date
Apr 30, 2008
Primary completion
May 31, 2009
Completion
Apr 2, 2019
Results posted
Nov 28, 2012
Last update
Jan 29, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion